AURKA and breast cancer: They observed that, in BRCA2-deficient breast cancer cells, the silencing of either AurkA or TPX2 causes a reduction in cell viability compared to BRCA2-proficient cells, suggesting that the survival of genomically unstable cancer cells depends on the AurkA/TPX2 signalling axis.